Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) – Pipeline Review, H1 2017’, provides in depth analysis on Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Infectious Disease, Genito Urinary System And Sex Hormones and Toxicology under development targeting Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)

– The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics and enlists all their major and minor projects

– The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Beta Pharma Inc

Eli Lilly and Company

FLX Bio Inc

G1 Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Teijin Pharma Ltd

Tiziana Life Sciences Plc

ViroStatics srl

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Overview

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Companies Involved in Therapeutics Development

Beta Pharma Inc

Eli Lilly and Company

FLX Bio Inc

G1 Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Teijin Pharma Ltd

Tiziana Life Sciences Plc

ViroStatics srl

XuanZhu Pharma Co Ltd

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-1178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-1748 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-925 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-1T100182 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-1T100183 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-1T101551 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-1T38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-381 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEC-80797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-123300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ribociclib succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-6390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trilaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voruciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-2370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Dormant Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Discontinued Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Product Development Milestones

Featured News & Press Releases

May 17, 2017: Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib at ASCO 2017

May 04, 2017: Breast Cancer Drug Palbociclib could be Temporarily Available to NHS Patients for Free

Apr 25, 2017: SignalRx to Present at the 12th Annual Drug Discovery Chemistry 2017 Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer

Apr 24, 2017: Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma

Apr 24, 2017: Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study Of Abemaciclib Demonstrated Superior Progression-Free Survival At Interim Analysis

Apr 21, 2017: Tiziana Life Sciences Announces Publication of Peer-Reviewed Paper from Positive Clinical Trial of Milciclib in Patients with Refractory Solid Tumors

Apr 04, 2017: Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting

Apr 03, 2017: SignalRx to Present at the AACR Annual Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer

Mar 31, 2017: IBRANCE (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer

Mar 20, 2017: Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival

Mar 17, 2017: KISQALI (ribociclib) Approved for the Treatment of HR+/HER2- Advanced Breast Cancer, Available for Order At Biologics

Mar 13, 2017: Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval

Mar 13, 2017: Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor

Feb 03, 2017: Breast cancer drug costs too high in relation to benefits for routine NHS funding

Jan 10, 2017: G1 Therapeutics Initiates Phase 2 trial of Trilaciclib in Triple-Negative Breast Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Beta Pharma Inc, H1 2017

Pipeline by Eli Lilly and Company, H1 2017

Pipeline by FLX Bio Inc, H1 2017

Pipeline by G1 Therapeutics Inc, H1 2017

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Pipeline by Novartis AG, H1 2017

Pipeline by Onconova Therapeutics Inc, H1 2017

Pipeline by Pfizer Inc, H1 2017

Pipeline by Teijin Pharma Ltd, H1 2017

Pipeline by Tiziana Life Sciences Plc, H1 2017

Pipeline by ViroStatics srl, H1 2017

Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports